Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Res Notes ; 11(1): 688, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-30285838

ABSTRACT

OBJECTIVE: To conduct a proof-of-concept study on preferential binding of polymeric IgA (pIgA) using a novel recombinant rabbit/human chimeric secretory component (cSC) and preliminary assessment of the diagnostic potential of virus-specific pIgA in discriminating acute hepatitis A, E, and C (HAV, HEV, HCV) patients and uninfected controls using an indirect enzyme-linked immunoassay. RESULTS: cSC binds > 0.06 µg/ml of purified human and mouse pIgA with negligible cross-reactivity against IgM and IgA. Virus-specific pIgA was significantly higher in serum of acute HAV (n = 6) and HEV (n = 12) patients than uninfected samples (HEV: p < 0.001; HAV: p = 0.001), and had low correlation with virus-specific IgM (HEV r: - 0.25, 95% CI - 0.88 to 0.71, p = 0.636; HAV r: 0.05, 95% CI - 0.54 to 0.60, p: 0.885). Anti-HCV pIgA peaked early in HCV seroconversion panels (n = 14), and was undetectable after 4 weeks post-primary bleed, even in ongoing infections, while serum anti-HCV IgA, IgG and IgM persisted. Patients with early acute HCV infection had significantly higher levels of anti-HCV pIgA compared to those with chronic infections (p < 0.01). The use of novel cSC demonstrates the presence of virus-specific pIgA in sera of patients with acute HAV, HEV, and HCV infection, and posits its potential utility as a diagnostic biomarker that warrants further validation on larger sample populations.


Subject(s)
Hepatitis A/blood , Hepatitis Antibodies/blood , Hepatitis C/blood , Hepatitis E/blood , Immunoglobulin A/analysis , Serologic Tests/standards , Biomarkers/blood , Humans , Proof of Concept Study
2.
ACS Chem Biol ; 9(9): 2074-81, 2014 Sep 19.
Article in English | MEDLINE | ID: mdl-24963694

ABSTRACT

Tyrosine (Tyr) sulfation is a common post-translational modification that is implicated in a variety of important biological processes, including the fusion and entry of human immunodeficiency virus type-1 (HIV-1). A number of sulfated Tyr (sTyr) residues on the N-terminus of the CCR5 chemokine receptor are involved in a crucial binding interaction with the gp120 HIV-1 envelope glycoprotein. Despite the established importance of these sTyr residues, the exact structural and functional role of this post-translational modification in HIV-1 infection is not fully understood. Detailed biological studies are hindered in part by the difficulty in accessing homogeneous sulfopeptides and sulfoproteins through biological expression and established synthetic techniques. Herein we describe an efficient approach to the synthesis of sulfopeptides bearing discrete sulfation patterns through the divergent, site-selective incorporation of sTyr residues on solid support. By employing three orthogonally protected Tyr building blocks and a solid-phase sulfation protocol, we demonstrate the synthesis of a library of target N-terminal CCR5(2-22) sulfoforms bearing discrete and differential sulfation at Tyr10, Tyr14, and Tyr15, from a single resin-bound intermediate. We demonstrate the importance of distinct sites of Tyr sulfation in binding gp120 through a competitive binding assay between the synthetic CCR5 sulfopeptides and an anti-gp120 monoclonal antibody. These studies revealed a critical role of sulfation at Tyr14 for binding and a possible additional role for sulfation at Tyr10. N-terminal CCR5 variants bearing a sTyr residue at position 14 were also found to complement viral entry into cells expressing an N-terminally truncated CCR5 receptor.


Subject(s)
HIV-1/pathogenicity , Peptide Library , Receptors, CCR5/chemistry , Receptors, CCR5/metabolism , Solid-Phase Synthesis Techniques/methods , Base Sequence , Cell Line/virology , HIV Envelope Protein gp120/metabolism , Host-Pathogen Interactions , Humans , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Tyrosine/chemistry
3.
J Immunol ; 176(12): 7489-94, 2006 Jun 15.
Article in English | MEDLINE | ID: mdl-16751395

ABSTRACT

The aggregation of cell surface FcRs by immune complexes induces a number of important Ab-dependent effector functions. However, despite numerous studies that examine receptor function, very little is known about the molecular organization of these receptors within the cell. In this study, protein complementation, mutagenesis, and ligand binding analyses demonstrate that human FcgammaRIIa is present as a noncovalent dimer form. Protein complementation studies found that FcgammaRIIa molecules are closely associated. Mutagenesis of the dimer interface, as identified by crystallographic analyses, did not affect ligand binding yet caused significant alteration to the magnitude and kinetics of receptor phosphorylation. The data suggest that the ligand binding and the dimer interface are distinct regions within the receptor, and noncovalent dimerization of FcgammaRIIa may be an essential feature of the FcgammaRIIa signaling cascade.


Subject(s)
Antigens, CD/genetics , Antigens, CD/metabolism , Receptors, IgG/genetics , Receptors, IgG/metabolism , Signal Transduction/genetics , Signal Transduction/immunology , Animals , Antigens, CD/physiology , Binding Sites/genetics , Binding Sites/immunology , CHO Cells , Cricetinae , Cricetulus , Dimerization , Down-Regulation/genetics , Humans , Immunoglobulin G/metabolism , Ligands , Methotrexate/metabolism , Mutagenesis, Site-Directed , Peptide Fragments/biosynthesis , Peptide Fragments/genetics , Peptide Fragments/metabolism , Phosphorylation , Proline/genetics , Receptors, IgG/physiology , Serine/genetics , Tetrahydrofolate Dehydrogenase/genetics , Tetrahydrofolate Dehydrogenase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...